A8236
AN-9
≥95% (HPLC)
别名:
Pivaloyloxymethyl butyrate, Pivanex
登录 查看组织和合同定价。
选择尺寸
变更视图
关于此项目
经验公式（希尔记法）:
C10H18O4
化学文摘社编号:
分子量:
202.25
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
assay
≥95% (HPLC)
form
oil
color
colorless to slightly yellow
solubility
DMSO: ≥10 mg/mL
storage temp.
−20°C
SMILES string
CCCC(=O)OCOC(=O)C(C)(C)C
InChI
1S/C10H18O4/c1-5-6-8(11)13-7-14-9(12)10(2,3)4/h5-7H2,1-4H3
InChI key
GYKLFBYWXZYSOW-UHFFFAOYSA-N
Application
AN-9 is a HDAC inhibitor with antimetastatic and antiangiogenic properties. These anticancer activities are thought to occur by reducing vascularization and the expression of bFGF and HIF-1α.
Biochem/physiol Actions
HDAC Inhibitor tested as an anti-cancer drug; butyric acid pro-drug
存储类别
12 - Non Combustible Liquids
wgk
nwg
flash_point_f
Not applicable
flash_point_c
Not applicable
Suzanne M Cutts et al.
Oncology research, 15(4), 199-213 (2007-09-08)
The anticancer drug Adriamycin is widely used in cancer chemotherapy and is classified as a topoisomerase II inhibitor. However, in the presence of formaldehyde, Adriamycin also forms high levels of DNA adducts. In this study, a new series of butyric
Belinda S Parker et al.
Cancer biology & therapy, 2(3), 259-263 (2003-07-25)
In addition to its action as a topoisomerase II poison, mitoxantrone is activated by formaldehyde to bind DNA, forming DNA-adducts specifically at 5'CpG and CpA sequences, with an enhancement of adducts at methylated CpG sites. The butyric acid prodrug, AN-9
S M Cutts et al.
Cancer research, 61(22), 8194-8202 (2001-11-24)
The interaction of Adriamycin and pivaloyloxymethyl butyrate (AN-9) was investigated in IMR-32 neuroblastoma and MCF-7 breast adenocarcinoma cells. Adriamycin is a widely used anticancer drug, whereas AN-9 is an anticancer agent presently undergoing Phase II clinical trials. The anticancer activity